identify and capitalize on possible collaboration, strategic partnering, acquisition or divestiture opportunities

Exhibit 10.10(a)

First Amendment to Exclusive License Agreement between
The University of Arizona and ProlX PHARMACEUTICALS, Inc.
Effective September 15, 2005

     This First Amendment to the Exclusive License Agreement between Prolx Pharmaceuticals, Inc., now Oncothyreon, Inc. (“LICENSEE”), and the Arizona Board of Regents on behalf of the University of Arizona (“LICENSOR”) for an invention entitled “Method of Preselecting Patients for Anti-VEGF, Anti-HIF-1 or Anti-Thioredoxin Therapy” (“Agreement”) is made effective as of the date of the last authorized signature below.

     The Licensee and University agree to amend the Agreement, as follows:

	1.		Revise Section 4.1, as follows:
			“4.1 LICENSEE agrees to pay LICENSOR an upfront License Fee of $5000 and a fee of $5000 for the First Amendment. Amendments subsequent to the First Amendment may be made without payment of a fee;”
	2.		Add a new Section 4.7, as follows:
			“4.7 In the event a Licensed Product is subject to any other royalty obligation pursuant to an agreement between the LICENSOR and LICENSEE, LICENSEE shall pay LICENSOR the greater of such applicable royalties for such Licensed Product, and in no event shall the royalties due to LICENSOR for such Licensed Product be cumulative;” and
	3.		Replace Schedule A with the attached Revised Schedule A.

     All other terms of the Agreement shall remain the same.

Agreed to by and between the Parties:

ARIZONA BOARD OF REGENTS On behalf of the University of Arizona,				ONCOTHYREON INC.
By:		/s/ Patrick L. Jones, PhD, MBA		By:		/s/ Robert L. Kirkman, MD
		Name: Patrick L. Jones, PhD, MBA				Name: Robert L. Kirkman, MD
		Title:   Director, Office of Technology Transfer				Title:   President and CEO
Date: 5th September 2008				Date: 28th November 2008

Revised Schedule A

Serial No.		Territory		Title		Filing Date		Status
10/288,888		US		N-Oxides and Derivatives of Melphalan for Treating Diseased States Associated With Hypoxia Inducible Factor		11/6/2002		Abandoned
10/929,156		US		N-Oxides and Derivatives of Melphalan for Treating Diseased States Associated With Hypoxia Inducible Factor		8/20/2004		Pending
2003291282		AU		N-Oxides and Derivatives of Melphalan for Treating Diseased States Associated With Hypoxia Inducible Factor		11/3/2003		Pending
2504496		CA		N-Oxides and Derivatives of Melphalan for Treating Diseased States Associated With Hypoxia Inducible Factor		11/3/2003		Pending
03768672.2		EP		N-Oxides and Derivatives of Melphalan for Treating Diseased States Associated With Hypoxia Inducible Factor		11/3/2003		Pending
2004-551738		JP		N-Oxides and Derivatives of Melphalan for Treating Diseased States Associated With Hypoxia Inducible Factor		11/3/2003		Pending
2005-004845		MX		N-Oxides and Derivatives of Melphalan for Treating Diseased States Associated With Hypoxia Inducible Factor		11/3/2003		Pending
PCT/US03/35266		PCT		N-Oxides and Derivatives of Melphalan for Treating Diseased States Associated With Hypoxia Inducible Factor		11/3/2003		Pending
60/487,562		US		Regulation of HIF Protein Levels via Deubiquination Pathway		7/14/2003		Expired

Serial No.		Territory		Title		Filing Date		Status
10/890,756		US		Regulation of HIF Protein Levels via Deubiquination Pathway		7/4/2004		Pending
				Regulation of HIF Protein Levels via Deubiquination Pathway		7/14/2004		Pending
60/602,151		US		Method of Pre-selecting Patients for Anti-VEGF, Anti-HIF-1 or Anti-Thioredoxin Therapy		8/17/2004		Expired
60/602,163		US		Monitoring Effects of PX-12 on Tumor Vascular Permeability		8/17/2004		Expired
11/206,526		US		Method of Preselecting Patients for Anti-VEGF, Anti-HIF-1 or Anti-Thioredoxin Therapy		8/17/2005		Pending
PCT/US06/29416		PCT		Method of Preselection Patients for Anti-VEGF, Anti-HIF-1 or Anti-Thioredoxin Therapy		8/17/2005		Reg./nat. Phases entered
2005277350		AU		Method of Preselection Patients for Anti-VEGF, Anti-HIF-1 or Anti-Thioredoxin Therapy		8/17/2005		Pending
2,577,312		CA		Method of Preselection Patients for Anti-VEGF, Anti-HIF-1 or Anti-Thioredoxin Therapy		8/17/2005		Pending
05808798.2		EP		Method of Preselection Patients for Anti-VEGF, Anti-HIF-1 or Anti-Thioredoxin Therapy		8/17/2005		Pending